http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2001006963-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 1999-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5689a7f2fea82ae5efc1580dd2b447fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb9acf8eae5c9a483ea88a100ae1ad86 |
| publicationDate | 2001-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2001006963-A1 |
| titleOfInvention | Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women |
| abstract | This invention describes the use of a once-a-month injection (once-a-month injectable) that contains an estrogenic and gestagenic component as an active ingredient for the production of a pharmaceutical agent for contraception and simultaneous hormone replacement therapy for perimenopausal and premenopausal women. n With this pharmaceutical agent, a more reliable contraceptive effect with a “natural” estrogen (without ethinylestradiol) with accompanying active therapy of the beginning estrogen-loss symptoms, as well as prevention of osteoporosis, is achieved. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8466139-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012000909-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2399566-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7456160-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8329680-B2 |
| priorityDate | 1995-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.